Share Name Share Symbol Market Type Share ISIN Share Description
Motif Bio LSE:MTFB London Ordinary Share GB00BVVT4H71 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 34.50p 34.75p 35.00p 35.25p 34.75p 35.25p 700,657 16:35:25
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -32.7 -28.3 - 90.85

Motif Bio (MTFB) Latest News

More Motif Bio News
Motif Bio Takeover Rumours

Motif Bio (MTFB) Share Charts

1 Year Motif Bio Chart

1 Year Motif Bio Chart

1 Month Motif Bio Chart

1 Month Motif Bio Chart

Intraday Motif Bio Chart

Intraday Motif Bio Chart

Motif Bio (MTFB) Discussions and Chat

Motif Bio (MTFB) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2017-11-20 16:53:4034.8623,1328,063.61O
2017-11-20 16:43:2234.502,000690.00O
2017-11-20 16:35:2534.507,9482,742.06UT
2017-11-20 16:29:2834.9619,6126,856.85O
2017-11-20 16:16:0634.965,4351,900.21O
View all Motif Bio trades in real-time

Motif Bio (MTFB) Top Chat Posts

DateSubject
20/11/2017
08:20
Motif Bio Daily Update: Motif Bio is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker MTFB. The last closing price for Motif Bio was 34.50p.
Motif Bio has a 4 week average price of 32.50p and a 12 week average price of 25.50p.
The 1 year high share price is 51.75p while the 1 year low share price is currently 21.50p.
There are currently 263,336,097 shares in issue and the average daily traded volume is 1,353,266 shares. The market capitalisation of Motif Bio is £90,850,953.47.
15/11/2017
09:13
timw3: nothing to move the share price till next year as tilly says. can only see it drifting
15/11/2017
08:24
timw3: so with no news till next year the share price is likely to fall!
15/11/2017
08:17
timw3: No further news now till next year? investors hate dry spells and usually means share price slipping!
08/11/2017
08:19
ramas: Problem is the market value will increase, unfortunately by giving away equity to the instis and dilution , not by share price appreciation, maybe a doubler but alas not a 100 bagger I fear
05/10/2017
08:43
mirabeau: From Beaufort Securities today: Our View: Truly excellent news! Motif management have delivered on every promise. Based on priority review, Iclaprim is set for a FDA decision in Q4'2018, followed by US commercial launch early in 2019, whereupon it will benefit from 10-years of Qualified Infectious Disease Product ('QIDP') marketing exclusivity. Of course additional funding will required within the next 12 months or so, in order to capture both the drug's full potential and further promote iclaprim while also funding the platform's development of follow-on indications. But the Motif Bio story has turned from 'high risk investment' to 'major commercial opportunity' and attracting such funding on a significantly higher valuation should present no difficulty although, realistically, this is more likely to be secured from potential industrial partners willing to pay handsomely for global territorial rights while the Board's own focus remains on overseeing commercialisation in the US. On the basis of ABSSSI identifying just the US market opportunity, specifically for those hospitalised patients having renal impairment with or without diabetes, of up to 26% of the 3.6 million ABSSSI patients hospitalised annually in the U.S. have kidney disease, suggesting iclaprim's annual market opportunity would be in the range of US$2.8bn. Globally it could be more than twice this for just the first indication, behind which there appears to be half-a-dozen more even larger opportunities. The pulmonary pneumonia one, for example in just the US, is probably twice the size of ABSSSI. Given past share price hiccups and the large retail element in its shareholder base, while spiking yesterday the equity still got nowhere near its true value. Investors should now at least hold on for Beaufort's price target of 110p/share, which will probably be reached when Motif management is able to confirm the signing-up of a major partner to take the non-US distribution rights for, say, an upfront payment of US$150m plus a 4% royalty, although that is possibly nine or so months away still. That said, any disbelievers still out there, could simply look at similar stage antibiotic developer, Nasdaq-listed Paratek Pharmaceuticals Inc. which presently has a valuation five times that of Motif, despite appearing somewhat inferior on the safety front. If the ordinary investor fails to recognise this unusual situation, one thing they can be sure of is that Big Pharma (Merck?) looking to expand their antibiotic portfolios will not. The starting point for discussions to assume outright control of Motif's assets is then likely to be something like 200p/share. Beaufort retains its Speculative Buy recommendation on Motif Bio with a 110p price target. Beaufort Securities
04/10/2017
17:22
gersemi: Motif Bio : The home plate beckons 13:15 04 Oct 2017 US Food & Drug administration approval is yet to be granted but iclaprim, which has fast-track status, is closing in on the promised land. Antibiotics INVESTMENT OVERVIEW: MTFB The Big Picture Patients are increasingly showing resistance to the effects of competing antibiotic vancomycin Motif Bio Plc (LON:MTFB) on Wednesday came a step closer to crossing home plate with its lead product, a next-generation antibiotic called iclaprim. For the early results of second phase III clinical study, called REVIVE-2, revealed the medication was both effective and well tolerated. Northland Capital’s Vadim Alexandre said the company had passed its biggest milestone to date, putting it on course to make a new drug submission in the first quarter next year. If all goes to plan, the market launch of iclaprim, which is also being developed for other indications such as hospital acquired infections, should take place in the second half of 2018. The shares shot up 41% to 51.69p, valuing Motif at £136mln. But that might not capture the full potential of Motif’s breakthrough. Northland’s Alexandre pointed out that when benchmarking Motif it might be worth using as a reference Paratek Pharmaceuticals, which is listed on NASDAQ and has a drug similar to iclaprim coming to market. The Americans, who tend to be a little punchier with their valuations, think it is worth US$700mln, or £527mln. The small-cap broker, finnCap, certainly thinks there’s some upside to the current share price with its £1 a share price target, which would get Motif to the quarter of a billion pound mark We’ll have to wait to see if there is a re-rating and just how far into the stratosphere this takes us, but all the ingredients are there. So what exactly has happened? Well we received what is called top-line data from the REVIVE-2 trial – that’s the bare-bones result from a months’ long study. The trial pitted Motif’s iclaprim treatment against vancomycin in patients with acute bacterial skin and skin structure infections (ABSSSI). The intent was to show that iclaprim was just as good as (the technical term is non-inferior to) the gold standard medication. The results did just that. Chief executive Graham Lumsden said the positive outcome was “testament to the incredible efforts of our team at Motif who have worked tirelessly to get us to this stage”. “We believe that these results validate our belief in iclaprim as a potential new antibiotic candidate for patients with serious and life-threatening infections. I thank the patients and clinicians who participated in this important study,” he added. Valuable asset If approved, the antibiotic will be an important new option for patients with ABSSSI, especially those who may also have kidney disease. This could apply to just over a quarter of the 3.6mln people annually who contract the acute skin infection in the US. “Unlike current standard of care antibiotics, in clinical trials to date, kidney toxicity has not been observed with iclaprim and dosage adjustment has not been required in patients with renal impairment,” said Lumsden. “Iclaprim may be an important option for the growing population of patients with ABSSSI and kidney disease who need a safe and effective antibiotic targeting Gram-positive bacteria, including MRSA." As mentioned above, this wasn’t the first phase III assessment successfully completed by Motif. Potential partnerships? REVIVE-1 was an identical study, but used different trial centres. It also rubber stamped the potential of iclaprim in patients with ABSSSI. Results from the first cohort also revealed it as a potential alternative treatment for those with kidney disease, which could end up being a a huge selling point. “[There are] unique clinical benefits aimed at prescribing clinicians that will, in our opinion drive iclaprim adoption at an accelerated pace,” said finnCap analyst Alex Pye. “Fixed dosage and renal sparing make a very compelling prescribing argument for treating patients with iclaprim over vancomycin, which increasingly shows signs of developing resistance.” Pye pointed out that Motif may be approached by larger pharmaceuticals companies who would look to sell the new product through their established sales networks and hospital contacts. He said this could drive market share gains beyond the 15% being predicted by the market. The finnCap number cruncher is sticking with his £1 a share valuation – for the time being - as US Food & Drug administration approval is yet to be granted. “But given iclaprim’s fast track status and potential appeal to clinicians, we believe that the long term prospects of the antimicrobial are robust,” he added. - From Proeactivv
04/10/2017
06:11
t-trader: Great news as expected and inline with R1. Looking forward to todays share price action.
03/10/2017
09:30
gersemi: Bought a few this morning after seeing this: Beaufort Securities Breakfast Alert: Motif Bio Plc, and others 08:13 02 Oct 2017 Motif Bio (LON:MTFB, 34.75p) – Speculative Buy The clinical stage biopharmaceutical company specialising in developing novel antibiotics, on Friday released its financial results for the half-year ended 30 June 2017. Net losses for the six months ended 30 June 2017 and 2016 were, very much as expected, US$29.7 million and US$14.2 million, respectively. Management strategy has focused on gaining approval for and commercialising iclaprim for ABSSSI and the continued development of iclaprim for additional indications to potentially broaden its use as a safe and effective antibiotic. In this regard, the necessary steps to initiate a Phase 3 clinical trial of iclaprim for the treatment of hospital-acquired bacterial pneumonia ('HABP'), including ventilator-associated bacterial pneumonia ('VABP'), have been completed. As of 30 June 2017, the Group had cash and cash equivalents of US$29.5 million, moving down to US$18.1 million by 22 September 2017. Post period, the Group has confirmed operations and strategic progress including that the last patient had completed the treatment phase in REVIVE-2, the second Phase 3 clinical trial investigating the safety and efficacy of iclaprim in patients with ABSSSI, as well the U.S. Food and Drug Administration ('FDA') granting Orphan Drug Designation to iclaprim for the treatment of Staphylococcus aureus lung infections in patients with cystic fibrosis. While awaiting the outcome of REVIVE-2, Motif will continue to refine its commercialisation strategy for iclaprim, both through the development of its go-to-market approach involving Medical Scientific Liaisons and targeting the highest antibiotic-prescribing hospitals, and leveraging the expertise of its Clinical Advisory Panel and other experts to understand how hospitals judge new products, including their expectations on data that will be required to enable rapid formulary access. The Board has submitted articles for publication in peer-reviewed scientific journals and abstracts for presentation at key scientific conferences, including Infection Diseases Week in October 2017, to build awareness and understanding in the medical community of the features and potential benefits of iclaprim. Our View: Not long to wait now. Potential short-term share price bonanza. Top-line results from REVIVE-2, which employ an identical protocol to REVIVE-1 but from different trial centres, are expected in the fourth quarter of 2017. Indeed, based on the scheduling of REVIVE-1, they could well appear in the next two to three weeks! Successful completion of the REVIVE-1 and REVIVE-2 Phase 3 trials is expected to satisfy both FDA and European Medicines Agency requirements for regulatory submission for an IV formulation of iclaprim in the treatment of ABSSSI. This offers a potential annual market opportunity valued well in excess of US$1bn (based on over 2 million ABSSSI admission/year in the US alone). On this basis, Beaufort anticipates submission of a New Drug Application ('NDA') in the United States in the first quarter of 2018 and a Marketing Authorisation Application ('MAA') for iclaprim for the treatment of ABSSSI in Europe in the first half of 2018. Assuming a positive trial outcome, existing cash will be sufficient to continue steering toward commercialisation although, of course, additional capital will required within the next 12 months or so to capture the drug's full potential and further promote iclaprim and while funding the platform's development of further indications. But by then, of course, the Motif Bio story should have turned from 'high risk investment' to 'major commercial opportunity' and attracting such funding on a much higher valuation should present no difficulty, although realistically this might well be found from potential industrial partners willing to pay handsomely for certain territorial rights, while the Board's own focus remains on overseeing commercialisation in the US. Had it not been for major shareholder, Amphion Innovations' recent seemingly distressed equity sales, by now Motif's share price would likely be more realistically reflecting the weight of the anticipated announcement. Thankfully, until the REVIVE-2 data at least, this sell-down has now completed and, while the forthcoming Top-line results make Motif something of an 'all-or-nothing' punt, the huge amount of diagnostic data already logged captures a much higher level of confidence than is normally the case. For those who understand these risks, Motif Bio represents a truly excellent buying opportunity. Beaufort retains its Speculative Buy recommendation on Motif Bio with a price target of 110p/share.
24/4/2017
10:10
mikeroot5: Trader Tim's thoughts: Motif Bio, I think will head toward 50p before encountering some resistance. Longer term, the trend looks favourable for the drug company. One thing to watch for is the raising of funds to finalise Phase III testing. The placing for stage one of Phase III, amid the delayed, fumbled NASDAQ listing, hurt the share price. However, management will be raising cash from a much stronger position this time around, so I don’t expect this placing to derail share price momentum significantly. hxxp://buff.ly/2oDfmLl
18/8/2015
09:53
regandharry5: Antibiotics in the news again, every time the over use of current antibiotics and how ineffiecent they are is raised the MTFB share price rises.
Motif Bio share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:30 V: D:20171121 06:41:34